Memantine Ratiopharm

Memantine Hydrochloride, the active ingredient in Memantine Ratiopharm, is an NMDA receptor antagonist presented as an oral tablet for oral administration. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and daily functioning.

GNH USA supplies Memantine Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU regulatory standards. Our quality‑assured supply chain ensures product integrity from manufacturing to end‑user.

Memantine Ratiopharm is used in the management of neurodegenerative disorders, specifically Alzheimer’s disease, by modulating glutamatergic activity.

- Alzheimer’s disease: improves cognition, daily functioning and behavioral symptoms in patients with moderate to severe disease.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: temporary mental clouding. - Fatigue: increased tiredness. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hallucinations: visual or auditory disturbances. - Suicidal thoughts: emergence of depressive ideation. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors. - Renal impairment: assess kidney function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes and adjust therapy as needed. - History of seizures: use with caution and observe for seizure activity. - Concomitant NMDA antagonists: avoid combined use to reduce additive toxicity. - Pregnancy: safety not established; weigh potential benefits against risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Amantadine: increased risk of dizziness and confusion. - Ketamine: additive NMDA antagonism may amplify neuro‑psychiatric effects. - Other NMDA antagonists: combined use can lead to excessive receptor blockade.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance dizziness or headache. - Anticholinergic agents: possible reduction in memantine efficacy. - Diuretics: potential for orthostatic hypotension.